ClinicalTrials.gg
CompletedNCT07422259Updated Feb 19, 2026

Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed

An interventional study of Reinnerva/Lubristil +G sterile eye drops (artificial tears) and Vismed sterile eye drops (artificial tears) in Keratoconjunctivitis Sicca, sponsored by Medivis SRL. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Medivis SRL · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The clinical investigation #1122 is a Post Market Clinical Follow Up Study on the EC marked medical device Reinnerva/Lubristil +G, sterile eye drops, compared to Vismed medical device, sterile eye drops, to demonstrate the clinical performance and tolerability of Reinnerva/Lubristil +G to stabilize the lacrimal film and improve the ocular surface condition in the cases of quali-quantitative alterations of the tear film .

Read the detailed description

The study aim was to demonstrate a significant improvement of the ocular surface condition with the use of Reinnerva/Lubristil +G that, based on its formulation: hydrates, stabilizes and protects the ocular surface in all cases of sensations of dryness, burning and ocular fatigue due to qualitative and quantitative alteration of the tear film.

02

Conditions studied

  • Keratoconjunctivitis Sicca
03

In context

Keratoconjunctivitis Sicca

85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.

This study's enrollment of 40 is below the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.

Browse Keratoconjunctivitis Sicca studies →

Lead sponsor

This is the only study on the registry with Medivis SRL as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male and female, aged 18 to 80 years
  • Alteration of the tear film or bilateral ocular surface discomfort resulting from one of the following conditions:

Patients receiving chronic therapy with antihypertensive eye drops; Patients receiving post-ocular surgery therapy for at least 15 days

  • At least two of the following symptoms of dry eye: burning, stinging, dry eye sensation, foreign body sensation, photophobia
  • At least two of the following:

Schirmer's test (8 mm lower in 5 minutes) BUT (Burning Time) less than 10 seconds Fluorescein Infection Infection (NEI) score ≥3

Exclusion criteria

Exclusion Criteria:

  • Active keratitis caused by herpes simplex, vaccinia virus, varicella-zoster, and other viral infections of the cornea and conjunctiva
  • Current bacterial, fungal, and tuberculosis infections
  • Corneal stromal perforations and ulcers
  • to any of the product components
  • Current ocular allergy or allergic rhinitis
  • Participation in a clinical trial in the month prior to the start of the study
  • Systemic anti-acne therapy in the 6 months prior to the start of the study
  • Any change in systemic therapy in the month prior to the start of the study
  • Contact lens use in the week prior to the start of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Reinnerva/Lubristil +G

    25 patients (17 of these participants were post-surgical and 8 glacomatous) received Reinnerva/Lubristil +G, sterile eye drops, 2 drops in 1 eye, twice daily for 60 days .

    Device: Reinnerva/Lubristil +G sterile eye drops (artificial tears)

  • Active comparator
    Vismed

    15 patients (11 of these participants were post-surgical and 4 glacomatous) received Vismed, sterile eye drops, 2 drops in 1 eye, 4 times daily for 60 days .

    Device: Vismed sterile eye drops (artificial tears)

Interventions

  • DeviceReinnerva/Lubristil +G sterile eye drops (artificial tears)

    2 drops instilled in 1 eye, 2 times daily, for 60 days

  • DeviceVismed sterile eye drops (artificial tears)

    2 drops instilled in 1 eye, 4 times daily, for 60 days

06

What researchers measure

Primary outcomes

  1. Clinical Performance and Benefit

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through subjective symptomatology expressed according to SANDE. The efficacy analysis has been evaluated by: \- Change in symptoms measured by a questionnaire (SANDE - Symptom Assessment in Dry Eye) to assess patient well-being. Unit of Measure: The SANDE is based on a visual analog scale (VAS). The patient answers only two questions regarding the frequency and severity of symptoms. For each question, a 100-millimeter horizontal line is provided: Symptom Frequency: From "Rarely" (0 mm) to "All the Time" (100 mm). Symptom Severity: From "Very Mild" (0 mm) to "Very Severe" (100 mm). The final measurement (Final Score) is a numerical value between 0 and 100. The total score is obtained by calculating the square root of the product of the two scales. Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

  2. Clinical Performance and Benefit

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through the Schirmer test. The efficacy analysis has been evaluated by: \- Schirmer test I (without anesthesia)- quantitative parameter Unit of Measure: The Schirmer test measures tear production in millimeters (mm) of strip wetting over a set time, typically 5 minutes. Results indicate the length of the moisture strip, with ≤ 5 mm in 5 minutes indicating severe dry eye, while \>15 mm is considered normal. Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

  3. Clinical Performance and Benefit

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through the NIK-BUT and BUT. The efficacy analysis has been evaluated by: Non-Invasive Keratograph Break-Up Time (NIKBUT)and BUT, objective, automated metric used in eye care to assess tear film stability. Unit of measure of NIKBUT: seconds (s). Normal tear film stability usually results in longer NIKBUT values, often exceeding 10 seconds, while dry eye conditions typically present with shorter, faster break-up times. Unit of measure of BUT: seconds (s). Normal result typically greater than 10 seconds, while values below 10 seconds (or especially under 5 seconds) indicate unstable, evaporative dry eye. Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

  4. Clinical Performance and Benefit

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through Tear meniscus thickness by keratography. The efficacy analysis has been evaluated by: \- Tear meniscus thickness by keratograph- quantitative parameter Unit of Measure: Tear meniscus height (TMH) measured by the Oculus Keratograph 5M (K5M) is reported in millimeters (mm), with normal values typically ranging between 0.2 mm and 0.4 mm. Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

  5. Clinical Performance and Benefit

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through fluorescein staining and its change between baseline and after 1-2 months of treatment . The efficacy analysis has been evaluated by: \- Fluorescein staining (NEI scheme - National Eye Institute Industry Workshop)/Corneal/Conjunctival evaluation with fluorescein - ordinal parameter. Unit of Measure: Subjective, graded scoring systems to assess corneal epithelial damage. The most common unit of measure is the NEI (National Eye Institute) Scale, a 0 to 3 scale for each of the five corneal regions (central, superior, inferior, nasal, temporal), with 0 = no stain and 3 = severe staining in each of 5 areas, based on staining density and location, totaling 0-15 point scale. Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

  6. Safety/Tolerability

    Adverse Events (AEs): Information regarding any medical device (eye drops) defect or event reported by a patient or investigator has been monitored at each investigational visit. Safety and tolerability analyses have included the number of adverse events occurred during the study in the treatment group and the percentage of patients with at least one adverse event judged to be related to the medical device under study

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

07

Study locations

1 site
  • UOC of Ophthalmology, AOU Policlinico "G. Martino"
    Messina, 98125, Italy
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared for privacy and confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2025, 2 months.

Of 10 interventional studies with no phase under Keratoconjunctivitis Sicca, half reached primary completion within 7 months of starting (the median); a quarter within 2 and three quarters within 17. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 19, 2026
StartActual
Jun 9, 2025
Primary completionActual
Sep 3, 2025
CompletionActual
Sep 3, 2025
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422259
Lead sponsor
Medivis SRL
Collaborators
University of Messina
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Jun 9, 2025
Primary completion
Sep 3, 2025
Completion
Sep 3, 2025
Last update
Feb 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion